REFERENCE
[1] Anon WHO recommends new name for monkeypox disease
[2] WHO 2022 Monkeypox
[3] Magnus P von, Andersen E K, Petersen K B and Birch-Andersen A 2009 A POX-LIKE DISEASE IN CYNOMOLGUS MONKEYS Acta Pathologica Microbiologica Scandinavica 46 156–76
[4] Ladnyj I D, Ziegler P and Kima E 1972 A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo Bull World Health Organ 46 593–7
[5] Nolen L D, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, Doty J, Hughes C M, Kabamba J, Malekani J, Bomponda P L, Lokota J I, Balilo M P, Likafi T, Lushima R S, Ilunga B K, Nkawa F, Pukuta E, Karhemere S, Tamfum J-J M, Nguete B, Wemakoy E O, McCollum A M and Reynolds M G 2016 Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo Emerg Infect Dis 22 1014–21
[6] Anon 1984 The current status of human monkeypox: Memorandum from a WHO Meeting Bull World Health Organ 62 703–13
[7] Kumar N, Acharya A, Gendelman H E and Byrareddy S N 2022 The 2022 outbreak and the pathobiology of the monkeypox virus J Autoimmun 131 102855
[8] WHO 2022 WHO Director-General’s statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox - 23 July 2022
[9] Anon 2022-23 Mpox (Monkeypox) Outbreak: Global Trends
[10] Cho C T and Wenner H A 1973 Monkeypox virus. Bacteriol Rev 37 1–18
[11] Anon 130s.pdf
[12] Kugelman J R, Johnston S C, Mulembakani P M, Kisalu N, Lee M S, Koroleva G, McCarthy S E, Gestole M C, Wolfe N D, Fair J N, Schneider B S, Wright L L, Huggins J, Whitehouse C A, Wemakoy E O, Muyembe-Tamfum J J, Hensley L E, Palacios G F and Rimoin A W 2014 Genomic Variability of Monkeypox Virus among Humans, Democratic Republic of the Congo Emerg Infect Dis 20 232–9
[13] Smith G L and Law M 2004 The exit of vaccinia virus from infected cells Virus Res 106 189–97
[14] Moss B 2001 Poxviridae: the viruses and their replication, vol. 2 Knipe, DMl
[15] Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong A A, Selekon B, Labouba I, Gonofio E C, Ouilibona R S, Simo Tchetgna H D, Feher M, Fontanet A, Kazanji M, Manuguerra J-C, Hassanin A, Gessain A and Nakoune E 2021 Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018 Sci Rep 11 13085
[16] Shchelkunov S N, Totmenin A V, Safronov P F, Mikheev M V, Gutorov V V, Ryazankina O I, Petrov N A, Babkin I V, Uvarova E A, Sandakhchiev L S, Sisler J R, Esposito J J, Damon I K, Jahrling P B and Moss B 2002 Analysis of the Monkeypox Virus Genome Virology 297 172–94
[17] Esposito J J and Knight J C 1985 Orthopoxvirus DNA: a comparison of restriction profiles and maps Virology 143 230–51
[18] Likos A M, Sammons S A, Olson V A, Frace A M, Li Y, Olsen-Rasmussen M, Davidson W, Galloway R, Khristova M L, Reynolds M G, Zhao H, Carroll D S, Curns A, Formenty P, Esposito J J, Regnery R L and Damon I K Y 2005 A tale of two clades: monkeypox viruses Journal of General Virology 86 2661–72
[19] Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A, Ndodo N, Ayansola O, Mboowa G, Bedford T, Neher R A, Roemer C, Hodcroft E, Tegally H, O’Toole Á, Rambaut A, Pybus O, Kraemer M U G, Wilkinson E, Isidro J, Borges V, Pinto M, Gomes J P, Freitas L, Resende P C, Lee R T C, Maurer-Stroh S, Baxter C, Lessells R, Ogwell A E, Kebede Y, Tessema S K and de Oliveira T 2022 Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus PLoS Biol 20 e3001769
[20] Anon 2022 Monkeypox: experts give virus variants new names
[21] Chen N, Li G, Liszewski M K, Atkinson J P, Jahrling P B, Feng Z, Schriewer J, Buck C, Wang C, Lefkowitz E J, Esposito J J, Harms T, Damon I K, Roper R L, Upton C and Buller R M L 2005 Virulence differences between monkeypox virus isolates from West Africa and the Congo basin Virology 340 46–63
[22] Parker S and Buller R M 2013 A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012 Future Virol 8 129–57
[23] Bunge E M, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer L R and Steffen R 2022 The changing epidemiology of human monkeypox—A potential threat? A systematic review PLoS Negl Trop Dis 16 e0010141
[24] Lum F-M, Torres-Ruesta A, Tay M Z, Lin R T P, Lye D C, Rénia L and Ng L F P 2022 Monkeypox: disease epidemiology, host immunity and clinical interventions Nat Rev Immunol 22 597–613
[25] Swiss Institute of Bioinformatics (SIB) 2022 Orthopoxvirus ~ ViralZone
[26] Pickup D J 2015 Extracellular Virions: The Advance Guard of Poxvirus Infections PLoS Pathog 11 e1004904
[27] Kmiec D and Kirchhoff F 2022 Monkeypox: A New Threat? Int J Mol Sci 23 7866
[28] Smith G L, Vanderplasschen A and Law M 2002 The formation and function of extracellular enveloped vaccinia virus J Gen Virol 83 2915–31
[29] Realegeno S, Priyamvada L, Kumar A, Blackburn J B, Hartloge C, Puschnik A S, Sambhara S, Olson V A, Carette J E, Lupashin V and Satheshkumar P S 2020 Conserved Oligomeric Golgi (COG) Complex Proteins Facilitate Orthopoxvirus Entry, Fusion and Spread Viruses 12 707
[30] Realegeno S, Puschnik A S, Kumar A, Goldsmith C, Burgado J, Sambhara S, Olson V A, Carroll D, Damon I, Hirata T, Kinoshita T, Carette J E and Satheshkumar P S 2017 Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GARP Complex in Extracellular Virus Formation J Virol 91 e00011-17
[31] Lopera J G, Falendysz E A, Rocke T E and Osorio J E 2015 Attenuation of monkeypox virus by deletion of genomic regions Virology 475 129–38
[32] Yu H, Bruneau R C, Brennan G and Rothenburg S 2021 Battle Royale: Innate Recognition of Poxviruses and Viral Immune Evasion Biomedicines 9 765
[33] Bartlett N W, Dumoutier L, Renauld J-C, Kotenko S V, McVey C E, Lee H-J and Smith G L 2004 A new member of the interleukin 10-related cytokine family encoded by a poxvirus J Gen Virol 85 1401–12
[34] Wong P-S, Sutejo R, Chen H, Ng S-H, Sugrue R J and Tan B-H 2018 A System Based-Approach to Examine Cytokine Response in Poxvirus-Infected Macrophages Viruses 10 692
[35] Lalani A S and McFadden G 1997 Secreted poxvirus chemokine binding proteins J Leukoc Biol 62 570–6
[36] Meng X, Schoggins J, Rose L, Cao J, Ploss A, Rice C M and Xiang Y 2012 C7L Family of Poxvirus Host Range Genes Inhibits Antiviral Activities Induced by Type I Interferons and Interferon Regulatory Factor 1 J Virol 86 4538–47
[37] Paust S, Senman B and von Andrian U H 2010 Adaptive immune responses mediated by natural killer cells Immunol Rev 235 286–96
[38] Jahrling P B, Hensley L E, Martinez M J, LeDuc J W, Rubins K H, Relman D A and Huggins J W 2004 Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox Proc Natl Acad Sci U S A 101 15196–200
[39] Song H, Josleyn N, Janosko K, Skinner J, Reeves R K, Cohen M, Jett C, Johnson R, Blaney J E, Bollinger L, Jennings G and Jahrling P B 2013 Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions PLoS One 8 e77804
[40] Strassburg M A 1982 The global eradication of smallpox American Journal of Infection Control 10 53–9
[41] Cherry J D, McIntosh K, Connor J D, Benenson A S, Alling D W, Rolfe U T, Todd W A, Schanberger J E and Mattheis M J 1977 Primary Percutaneous Vaccination The Journal of Infectious Diseases 135 145–54
[42] Keasey S, Pugh C, Tikhonov A, Chen G, Schweitzer B, Nalca A and Ulrich R G 2010 Proteomic Basis of the Antibody Response to Monkeypox Virus Infection Examined in Cynomolgus Macaques and a Comparison to Human Smallpox Vaccination PLOS ONE 5 e15547
[43] MacLeod M K L, Clambey E T, Kappler J W and Marrack P 2009 CD4 memory T cells: what are they and what can they do? Semin Immunol 21 53–61
[44] Hickman H D, Reynoso G V, Ngudiankama B F, Rubin E J, Magadán J G, Cush S S, Gibbs J, Molon B, Bronte V, Bennink J R and Yewdell J W 2013 Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin Cell Host Microbe 13 155–68
[45] Goulding J, Abboud G, Tahiliani V, Desai P, Hutchinson T and Salek-Ardakani S 2014 CD8 T cells utilize IFN-γ to protect against the lethal effects of a respiratory poxvirus infection J Immunol 192 5415–25
[46] Iwasaki A and Medzhitov R 2010 Regulation of adaptive immunity by the innate immune system Science 327 291–5
[47] Kawai T and Akira S 2006 Innate immune recognition of viral infection Nat Immunol 7 131–7
[48] Rathinam V A K and Fitzgerald K A 2011 Innate Immune sensing of DNA viruses Virology 411 153–62
[49] O’Neill L A J and Bowie A G 2007 The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling Nat Rev Immunol 7 353–64
[50] Shchelkunov S N 2012 Orthopoxvirus Genes That Mediate Disease Virulence and Host Tropism Adv Virol 2012 524743
[51] Shi Y 2004 Caspase activation, inhibition, and reactivation: A mechanistic view Protein Sci 13 1979–87
[52] Youle R J and Strasser A 2008 The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 47–59
[53] Arndt W D, White S D, Johnson B P, Huynh T, Liao J, Harrington H, Cotsmire S, Kibler K V, Langland J and Jacobs B L 2016 Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus Virology 497 125–35
[54] Arndt W D, Cotsmire S, Trainor K, Harrington H, Hauns K, Kibler K V, Huynh T P and Jacobs B L 2015 Evasion of the Innate Immune Type I Interferon System by Monkeypox Virus J Virol 89 10489–99
[55] Hudson P N, Self J, Weiss S, Braden Z, Xiao Y, Girgis N M, Emerson G, Hughes C, Sammons S A, Isaacs S N, Damon I K and Olson V A 2012 Elucidating the Role of the Complement Control Protein in Monkeypox Pathogenicity PLoS One 7 e35086
[56] Jezek Z, Szczeniowski M, Paluku K M and Mutombo M 1987 Human monkeypox: clinical features of 282 patients J Infect Dis 156 293–8
[57] Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C and Zumla A 2019 Human Monkeypox Infect Dis Clin North Am 33 1027–43
[58] Adler H, Gould S, Hine P, Snell L B, Wong W, Houlihan C F, Osborne J C, Rampling T, Beadsworth M B, Duncan C J, Dunning J, Fletcher T E, Hunter E R, Jacobs M, Khoo S H, Newsholme W, Porter D, Porter R J, Ratcliffe L, Schmid M L, Semple M G, Tunbridge A J, Wingfield T, Price N M, and NHS England High Consequence Infectious Diseases (Airborne) Network 2022 Clinical features and management of human monkeypox: a retrospective observational study in the UK Lancet Infect Dis 22 1153–62
[59] Ogoina D, Iroezindu M, James H I, Oladokun R, Yinka-Ogunleye A, Wakama P, Otike-Odibi B, Usman L M, Obazee E, Aruna O and Ihekweazu C 2020 Clinical Course and Outcome of Human Monkeypox in Nigeria Clin Infect Dis 71 e210–4
[60] Hutson C L, Carroll D S, Gallardo-Romero N, Weiss S, Clemmons C, Hughes C M, Salzer J S, Olson V A, Abel J, Karem K L and Damon I K 2011 Monkeypox disease transmission in an experimental setting: prairie dog animal model PLoS One 6 e28295
[61] CDC 2022 Monkeypox in the U.S. Centers for Disease Control and Prevention
[62] Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, Brown C S, Chow Y, Edeghere O, Florence I, Logan S, Manley P, Crowe W, McAuley A, Shankar A G, Mora-Peris B, Paranthaman K, Prochazka M, Ryan C, Simons D, Vipond R, Byers C, Watkins N A, Welfare W, Whittaker E, Dewsnap C, Wilson A, Young Y, Chand M, Riley S, Hopkins S, Charlett A, Finnie T, McAuslane H, Weeple B, Fifer H, Sinka K, Edwards D, Lopez-Bernal J, Rampling T, Lee A, Mellon D, Kliner M, Young N, Makki S, Coles S, Shepherd W, Latham V, Tabor R, Graham A, Yuan J, MacDonald N, Vusirikala A, Ma T, Cooper K and Saavedra-Campos M 2022 Community transmission of monkeypox in the United Kingdom, April to May 2022 Euro Surveill 27 2200422
[63] Philpott D, Hughes C M, Alroy K A, Kerins J L, Pavlick J, Asbel L, Crawley A, Newman A P, Spencer H, Feldpausch A, Cogswell K, Davis K R, Chen J, Henderson T, Murphy K, Barnes M, Hopkins B, Fill M-M A, Mangla A T, Perella D, Barnes A, Hughes S, Griffith J, Berns A L, Milroy L, Blake H, Sievers M M, Marzan-Rodriguez M, Tori M, Black S R, Kopping E, Ruberto I, Maxted A, Sharma A, Tarter K, Jones S A, White B, Chatelain R, Russo M, Gillani S, Bornstein E, White S L, Johnson S A, Ortega E, Saathoff-Huber L, Syed A, Wills A, Anderson B J, Oster A M, Christie A, McQuiston J, McCollum A M, Rao A K, Negrón M E, Griffin I, Khan M, Ogale Y, Sims E, Lash R R, Rainey J J, Charniga K, Waltenburg M A, Dawson P, Quilter L A S, Rushmore J, Stenger M R, Kachur R E, Whitehill F, Jackson K A, Collins J, Signs K, Richardson G, Hand J, Spence-Davizon E, Steidley B, Osborne M, Soliva S, Cook S, Ayuk-Takor L, Willut C, Snively A, Lehnertz N, Quilliam D N, Durham M, Cardona-Gerena I R, Bell L J, Control E, Kuljanin M, Gibbons-Burgener S, Westergaard R, Sosa L E, Beddo M, Donahue M, Koirala S, Dewart C, Murray-Thompson J, Peake L, Holshue M L, et al 2022 Epidemiologic and Clinical Characteristics of Monkeypox Cases — United States, May 17–July 22, 2022 MMWR Morb Mortal Wkly Rep 71 1018–22
[64] Daskalakis D, McClung R P, Mena L, Mermin J, and Centers for Disease Control and Prevention’s Monkeypox Response Team 2022 Monkeypox: Avoiding the Mistakes of Past Infectious Disease Epidemics Ann Intern Med 175 1177–8
[65] Commissioner O of the 2020 FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox FDA
[66] Volz A and Sutter G 2017 Modified Vaccinia Virus Ankara Adv Virus Res 97 187–243
[67] Yang G, Pevear D C, Davies M H, Collett M S, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins J W, Baker R O, Buller R L M, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D and Jordan R 2005 An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge J Virol 79 13139–49
[68] Russo A T, Berhanu A, Bigger C B, Prigge J, Silvera P M, Grosenbach D W and Hruby D 2020 Co-administration of tecovirimat and ACAM2000TM in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge Vaccine 38 644–54
[69] Anon Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | NEJM
[70] Anon FDA Mpox Response | FDA
[71] Russo A T, Grosenbach D W, Chinsangaram J, Honeychurch K M, Long P G, Lovejoy C, Maiti B, Meara I and Hruby D E 2021 An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications Expert Review of Anti-infective Therapy 19 331–44
[72] Ali Y, Imtiaz H, Tahir M M, Gul F, Saddozai U A K, ur Rehman A, Ren Z-G, Khattak S and Ji X-Y 2023 Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus Viruses 15 570
[73] Chen Z-R, Lv Q-L, Peng H-W, Liu X-Y, Hu W-L and Hu J-F 2022 Drug screening against F13 protein, the target of tecovirimat, as potential therapies for monkeypox virus J Infect
[74] Andrei G and Snoeck R 2010 Cidofovir Activity against Poxvirus Infections Viruses 2 2803–30
[75] Meyer H, Ehmann R and Smith G L 2020 Smallpox in the Post-Eradication Era Viruses 12 138
[76] Jezek Z, Marennikova S S, Mutumbo M, Nakano J H, Paluku K M and Szczeniowski M 1986 Human monkeypox: a study of 2,510 contacts of 214 patients J Infect Dis 154 551–5